Role of induction therapy. Surgical resection of non-small cell lung cancer after induction therapy.

Thoracic Surgery Clinics

Volumn 23, Issue 3, 2013, Pages 273-285

  Ripley, R Taylor ^a   Rusch, Valerie W ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Induction therapy; Stage III lung cancer; Surgery

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUORODEOXYGLUCOSE; GEFITINIB; MITOMYCIN; PACLITAXEL; VINBLASTINE;

ADJUVANT CHEMORADIOTHERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMORBIDITY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; ENDOBRONCHIAL ULTRASONOGRAPHY; HUMAN; INDUCTION CHEMOTHERAPY; LONG TERM SURVIVAL; LUNG FUNCTION; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MEDIASTINOSCOPY; MEDIASTINUM LYMPH NODE; META ANALYSIS (TOPIC); MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCOAST TUMOR; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SENSITIVITY AND SPECIFICITY; SURGICAL MORTALITY; THORACOTOMY;

INDUCTION THERAPY; STAGE III LUNG CANCER; SURGERY;

CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; NEOADJUVANT THERAPY; PNEUMONECTOMY;

EID: 84881370205     PISSN: 15474127     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thorsurg.2013.04.004     Document Type: Review

References (96)

1. Goldstraw P., Crowley J., Chansky K., et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. JThorac Oncol 2007, 2:706-714.
2. Martini N., Flehinger B.J. The role of surgery in N2 lung cancer. Surg Clin North Am 1987, 67:1037-1049.
3. Martini N., Kris M.G., Flehinger B.J., et al. Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg 1993, 55:1365-1374.
4. Roth J.A., Atkinson E.N., Fossella F., et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. Lung Cancer 1998, 21:1-6.
5. Roth J.A., Fossella F., Komaki R., et al. Arandomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. JNatl Cancer Inst 1994, 86:673-680.
6. Rosell R., Gómez-Codina J., Camps C., et al. Arandomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. NEngl J Med 1994, 330:153-158.
7. Song W.A., Zhou N.K., Wang W., et al. Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer: an updated meta-analysis of 13 randomized control trials. JThorac Oncol 2010, 5(4):510-516.
8. Sugarbaker D.J., Herndon J., Kohman L.J., et al. The Cancer and Leukemia Group B Thoracic Surgery Group. Results of Cancer and Leukemia Group B protocol 8935. A multiinstitutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. JThorac Cardiovasc Surg 1995, 109:473-485.
9. Albain K.S., Rusch V.W., Crowley J.J., et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small cell lung cancer: mature results of Southwest Oncology Group Phase II study 8805. JClin Oncol 1995, 13:1880-1892.
10. Albain K.S., Swann R.S., Rusch V.W., et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small cell lung cancer: a phase III randomised controlled trial. Lancet 2009, 374:379-386.
11. Van Meerbeeck J.P., Kramer G.W., Van Schil P.E., et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in Stage IIIA-N2 non-small cell lung cancer. JNatl Cancer Inst 2007, 99:442-450.
12. Arriagada R., Dunant A., Pignon J.P., et al. Long-term results of the International Adjuvant Lung Cancer Trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. JClin Oncol 2010, 28(1):35-42.
13. Pignon J.P., Tribodet H., Scagliotti G.V., et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. JClin Oncol 2008, 26(21):3552-3559.
14. Douillard J.Y., Rosell R., De Lena M., et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006, 7:719-727.
15. Winton T., Livingston R., Johnson D., et al. Vinorelbine plus cisplatin vs. observation in resected non-small cell lung cancer. NEngl J Med 2005, 352:2589-2597.
16. Strauss G.M., Herndon J.E., Maddaus M.A., et al. Adjuvant paclitaxel plus carboplatin compared with observation in Stage IB non-small cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. JClin Oncol 2008, 26(31):5043-5051.
17. Thomas M., Rübe C., Hoffknecht P., et al. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small cell lung cancer. Lancet Oncol 2008, 9(7):636-648.
18. Higgins K., Chino J.P., Marks L.B., et al. Preoperative chemotherapy versus preoperative chemoradiotherapy for stage III (N2) non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2009, 75(5):1462-1467.
19. Shah A.A., Berry M.F., Tzao C., et al. Induction chemoradiation is not superior to induction chemotherapy alone in stage IIIA lung cancer. Ann Thorac Surg 2012, 93(6):1807-1812.
20. de Cabanves Candela S., Detterbeck F.C. Asystematic review of restaging after induction therapy for stage IIIA lung cancer: prediction of pathologic stage. JThorac Oncol 2010, 5(3):389-398.
21. Rebollo-Aguirre A.C., Ramos-Font C., Villegas Portero R., et al. Is FDG-PET suitable for evaluating neoadjuvant therapy in non-small cell lung cancer? Evidence with systematic review of the literature. JSurg Oncol 2010, 101(6):486-494.
22. Stigt J.A., Oostdjik A.H., Timmer P.R., et al. Comparison of EUS-guided fine needle aspiration and integrated PET-CT in restaging after treatment for locally advanced non-small cell lung cancer. Lung Cancer 2009, 66(2):198-204.
23. Kunst P.W., Lee P., Paul M.A., et al. Restaging of mediastinal nodes with transbronchial needle aspiration after induction chemoradiation for locally advanced non-small cell lung cancer. JThorac Oncol 2007, 2(10):912-915.
24. Annema J.T., Veseliç M., Versteegh M.I., et al. Mediastinal restaging: EUS-FNA offers a new perspective. Lung Cancer 2003, 42:311-318.
25. Herth F.J., Annema J.T., Eberhardt R., et al. Endobronchial ultrasound with transbronchial needle aspiration for restaging the mediastinum in lung cancer. JClin Oncol 2008, 26(20):3346-3350.
26. Varadarajulu S., Eloubeidi M. Can endoscopic ultrasonography-guided fine-needle aspiration predict response to chemoradiation in non-small cell lung cancer? A pilot study. Respiration 2006, 73(2):213-220.
27. Van Schil P., van Meerbeeck J., Kramer G., et al. Morbidity and mortality in the surgery arm of EORTC 08941 trial. Eur Respir J 2005, 26:1-6.
28. Barnett S.A., Rusch V.W., Zheng J., et al. Contemporary results of surgical resection of non-small cell lung cancer after induction therapy: a review of 549 consecutive cases. JThorac Oncol 2011, 6(9):1530-1536.
29. Weder W., Collaud S., Eberhardt W.E., et al. Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non-small cell lung cancer. JThorac Cardiovasc Surg 2010, 139:1424-1430.
30. Cerfolio R.J., Bryant A.S., Spencer S.A., et al. Pulmonary resection after high-dose and low-dose chest irradiation. Ann Thorac Surg 2005, 80:1224-1230.
31. Kwong K.F., Edelman M.J., Suntharalingam M., et al. High-dose radiotherapy in trimodality treatment of Pancoast tumors results in high pathologic complete response rates and excellent long-term survival. JThorac Cardiovasc Surg 2005, 129:1250-1257.
32. Daly B.D., Fernando H.C., Ketchedjian A., et al. Pneumonectomy after high-dose radiation and concurrent chemotherapy for nonsmall cell lung cancer. Ann Thorac Surg 2006, 82:227-231.
33. Edelman M.J., Suntharalingam M., Burrows W., et al. Phase I/II trial of hyperfractionated radiation and chemotherapy followed by surgery in Stage III lung cancer. Ann Thorac Surg 2008, 86:903-911.
34. Krasna M.J., Gamliel Z., Burrows W.M., et al. Pneumonectomy for lung cancer after preoperative concurrent chemotherapy and high-dose radiation. Ann Thorac Surg 2010, 89(1):200-206.
35. Martin J., Ginsberg R.J., Abolhoda A., et al. Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy. Ann Thorac Surg 2001, 72:1149-1154.
36. Evans N.R., Li S., Wright C.D., et al. The impact of induction therapy on morbidity and operative mortality after resection of primary lung cancer. JThorac Cardiovasc Surg 2010, 139(4):991-996.
37. Kim A.W., Boffa D.J., Wang Z., et al. An analysis, systematic review, and meta-analysis of the perioperative mortality after neoadjuvant therapy and penumonectomy for non-small cell lung cancer. JThorac Cardiovasc Surg 2012, 143(1):55-63.
38. Doddoli C., Barlesi F., Trousse D., et al. One hundred consecutive pneumonectomies after induction therapy for non-small cell lung cancer: an uncertain balance between risks and benefits. JThorac Cardiovasc Surg 2005, 130:416-425.
39. Martin J., Ginsberg R.J., Venkatraman E.S., et al. Long term results of combined modality therapy in resectable non-small cell lung cancer. JClin Oncol 2002, 20(8):1989-1995.
40. Kim A.W., Faber L.P., Warren W.H., et al. Pneumonectomy after chemoradiation therapy for non-small cell lung cancer: does "side" really matter?. Ann Thorac Surg 2009, 88:937-944.
41. Allen A.M., Mentzer S.J., Yeap B.Y., et al. Pneumonectomy after chemoradiation: the Dana-Farber Cancer Institute/Brigham and Women's Hospital experience. Cancer 2008, 112(5):1106-1113.
42. Mansour Z., Kochetkova E.A., Ducrocq X., et al. Induction chemotherapy does not increase the operative risk of pneumonectomy!. Eur J Cardiothorac Surg 2007, 31:181-185.
43. Doddoli C., Thomas P., Thirion X., et al. Postoperative complications in relation with induction therapy forlung cancer. Eur J Cardiothorac Surg 2001, 20:385-390.
44. Pancoast H.K. Superior pulmonary sulcus tumor. JAm Med Assoc 1932, 99:1391-1396.
45. Chardack W.M., MacCallum J.D. Pancoast tumor (five year survival without recurrence or metastases following radical resection and postoperative irradiation). JThorac Surg 1956, 31:535-542.
46. Shaw R.R., Paulson D.L., Kee J.L. Treatment of the superior sulcus tumor by irradiation followed by resection. Ann Surg 1961, 154:29-40.
47. Rusch V.W., Parekh K.R., Leon L., et al. Factors determining outcome after surgical resection of T3 and T4 lung cancers of the superior sulcus. JThorac Cardiovasc Surg 2000, 119:1147-1153.
48. Dartevelle P.G., Chapelier A.R., Macchiarini P., et al. Anterior transcervical-thoracic approach for radical resection of lung tumors invading the thoracic inlet. JThorac Cardiovasc Surg 1993, 105:1025-1034.
49. Rusch V.W., Giroux D.J., Kraut M.J., et al. Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: initial results of Southwest Oncology Group trial 9416 (Intergroup trial 0160). JThorac Cardiovasc Surg 2001, 121:472-483.
50. Rusch V.W., Giroux D.J., Kraut M.J., et al. Induction chemoradiation and surgical resection for superior sulcus non-small cell lung carcinomas: long-term results of Southwest Oncology Group trial 9416 (Intergroup trial 0160). JClin Oncol 2007, 25:313-318.
51. Rusch V.W. Management of Pancoast tumours. Lancet Oncol 2006, 7(12):997-1005.
52. Masaoka A., Ito Y., Yasumitsu T. Anterior approach for tumor of the superior sulcus. JThorac Cardiovasc Surg 1979, 78:413-415.
53. Niwa H., Masaoka A., Yamakawa Y., et al. Surgical therapy for apical invasive lung cancer: different approaches according to tumor location. Lung Cancer 1993, 10:63-71.
54. Grunenwald D., Spaggiari L. Transmanubrial osteomuscular sparing approach for apical chest tumors. Ann Thorac Surg 1997, 63:563-566.
55. Bilsky M.H., Vitaz T.W., Boland P.J., et al. Surgical treatment of superior sulcus tumors with spinal and brachial plexus involvement. JNeurosurg 2002, 97(Suppl 3):301-309.
56. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
57. Rocha Lima C.M., Herndon J.E., Kosty M., et al. Therapy choices among older patients with lung carcinoma: an evaluation of two trials in the Cancer and Leukemia Group B. Cancer 2002, 94(1):181-187.
58. Peake M.D., Thompson S., Lowe D., Participating Centers, et al. Ageism in the management of lung cancer. Age Ageing 2003, 32(2):171-177.
59. Owonikoko T.K., Ragin C.C., Belani C.P., et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. JClin Oncol 2007, 25(35):5570-5577.
60. Smith T.J., Penberthy L., Desch C.E., et al. Differences in initial treatment patters and outcomes of lung cancer in the elderly. Lung Cancer 1995, 13(3):235-252.
61. Oxnard G.R., Fidias P., Muzikansky A., et al. Non-small cell lung cancer in octogenarians: treatment practices and preferences. JThorac Oncol 2007, 2(11):1029-1035.
62. Cudennec T., Gendry T., Labrune S., et al. Use of a simplified geriatric evaluation in thoracic oncology. Lung Cancer 2010, 67(2):232-236.
63. Girre V., Falcou M.C., Gisselbrecht M., et al. Does a geriatric oncology consultation modify the cancer treatment plan for elderly patients?. JGerontol A Biol Sci Med Sci 2008, 63(7):724-730.
64. Früh M., Rolland E., Pignon J.P., et al. Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small cell lung cancer. JClin Oncol 2008, 26(21):3573-3581.
65. Pepe C., Hasan B., Winton T.L., et al. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. JClin Oncol 2007, 25(12):1553-1561.
66. Gridelli C., Maione P., Comunale D., et al. Adjuvant chemotherapy in elderly patients with non-small-cell lung cancer. Cancer Control 2007, 14(1):57-62.
67. Gridelli C., Langer C., Maione P., et al. Lung cancer in the elderly. JClin Oncol 2007, 25(14):1898-1907.
68. Rivera C., Jougon J., Dahan M., et al. Are postoperative consequences of neoadjuvant chemotherapy for non-small cell lung cancer more severe in elderly patients?. Lung Cancer 2012, 76(2):216-221.
69. Pisters K.M., Vallières E., Crowley J.J., et al. Surgery with or without preoperative paclitaxel and carboplatin in early stage non-small cell lung cancer: Southwest Oncology Group trial S9900, an intergroup, randomized, phase III trial. JClin Oncol 2010, 28(11):1843-1849.
70. Scagliotti G.V., Pastorino U., Vansteenkiste J.F., et al. Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small cell lung cancer. JClin Oncol 2012, 30:172-178.
71. Gilligan D., Nicolson M., Smith I., et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet 2007, 369:1929-1937.
72. Felip E., Rosell R., Maestre J.A., et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small cell lung cancer. JClin Oncol 2010, 28(19):3138-3145.
73. Lynch T.J., Bell D.W., Sordelia R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. NEngl J Med 2004, 350(21):2129-2139.
74. Reungwetwattana T., Weroha S.J., Molina J.R. Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small cell lung cancer (NSCLC). Clin Lung Cancer 2012, 13(4):252-266.
75. Rizvi N.A., Rusch V., Pao W., et al. Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene. Clin Cancer Res 2011, 17(10):3500-3506.
76. Schaake E.E., Kappers I., Codrington H.E., et al. Tumor response and toxicity of neoadjuvant erlotinib in patients with early-stage non-small cell lung cancer. JClin Oncol 2012, 30(22):2731-2738.
77. Burkes R.L., Ginsberg R.J., Shepherd F.A., et al. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small cell lung cancer: results of the Toronto phase II trial. JClin Oncol 1992, 10:580-586.
78. Rosell R., Gómez-Codina J., Camps C., et al. Preresectional chemotherapy in stage IIIA non-small cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 1999, 47:7-14.
79. Van Zandwijk N., Smit E.F., Kramer G.W., et al. Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955). JClin Oncol 2000, 18(14):2658-2664.
80. Betticher D.C., Hsu Schmitz S.F., Tötsch M., et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small cell lung cancer: a multicenter phase II trial. JClin Oncol 2003, 21:1752-1759.
81. Nagai K., Tsuchiya R., Mori T., et al. Arandomized trial of comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209). JThorac Cardiovasc Surg 2003, 125:254-260.
82. O'Brien M.E., Splinter T., Smit E.F., et al. Carboplatin and paclitaxol (Taxol) as an induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer. An EORTC phase II study (EORTC 08958). Eur J Cancer 2003, 39(10):1416-1422.
83. Garrido P., González-Larriba J.L., Insa A., et al. Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non-small cell lung cancer patients: the Spanish Lung Cancer Group trial 9901. JClin Oncol 2007, 25(30):4736-4742.
84. Mathisen D.J., Wain J.C., Wright C., et al. Assessment of preoperative accelerated radiotherapy and chemotherapy in stage IIIA (N2) non-small cell lung cancer. JThorac Cardiovasc Surg 1996, 111:123-133.
85. Katayama H., Ueoka H., Kiura K., et al. Preoperative concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced non-small cell lung cancer. Br J Cancer 2004, 90(5):979-984.
86. Steger V., Walles T., Kosan B., et al. Trimodal therapy for histologically proven N2/3 non-small cell lung cancer: mid-term results and indicators for survival. Ann Thorac Surg 2009, 87(6):1676-1683.
87. Paulson D.L. Carcinomas in the superior pulmonary sulcus. JThorac Cardiovasc Surg 1975, 70:1095-1104.
88. Attar S., Miller J.E., Satterfield J., et al. Pancoast's tumor: irradiation or surgery?. Ann Thorac Surg 1979, 28:578-586.
89. Ginsberg R.J., Martini N., Zaman M., et al. Influence of surgical resection and brachytherapy in the management of superior sulcus tumor. Ann Thorac Surg 1994, 57:1440-1445.
90. Maggi G., Casadio C., Pischedda F., et al. Combined radiosurgical treatment of Pancoast tumor. Ann Thorac Surg 1994, 57:198-202.
91. Hagan M.P., Choi N.C., Mathisen D.J., et al. Superior sulcus lung tumors: impact of local control on survival. JThorac Cardiovasc Surg 1999, 117:1086-1094.
92. Komaki R., Roth J.A., Walsh G.L., et al. Outcome predictors for 143 patients with superior sulcus tumor treated by multidisciplinary approach at the University of Texas M.D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys 2000, 48:347-354.
93. Martinod E., D'Audiffret A., Thomas P., et al. Management of superior sulcus tumors: experience with 139 cases treated by surgical resection. Ann Thorac Surg 2002, 73:1534-1540.
94. Marra A., Eberhardt W., Pöttgen C., et al. Induction chemotherapy, concurrent chemoradiation and surgery for Pancoast tumour. Eur Respir J 2007, 29:117-127.
95. Pourel N., Santelmo N., Naafa N., et al. Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response. Eur J Cardiothorac Surg 2008, 33:829-836.
96. Kunitoh H., Kato H., Tsuboi M., et al. Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small cell lung cancers: report of Japan Clinical Oncology Group Trial 9806. JClin Oncol 2008, 26:644-649.